Hovione to create new campus and 100 jobs at New Jersey site
The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing
Spray drying and particle engineering specialist Hovione has announced it is expanding its facilities at its East Windsor, New Jersey site with the creation of a state-of-the-art Hovione Campus.
The new 31,000-sq. ft (2900m2) building will be next to the company's existing site in New Jersey, laying the foundations of a Hovione Campus, and will bring additional commercial spray drying capacity online by 2023.
It will also allow the company to respond to customers favouring US-based manufacturing, from development all the way to commercial.
According to Hovione, the increased capacity will solidify its integrated offer ― API, particle engineering, drug product ― in the region.
The expansion, which was announced during CPHI Worldwide, in Milan, by Guy Villax, CEO, and Jean-Luc Herbeaux, COO, forms part of the company's $170 million global expansion strategy to increase capacity at its sites in the US, Ireland and Portugal leading to a global capacity increase of approximately 25%. The increased capacity will also create up to 100 jobs during the course of the next few years.
Filipe Tomás, General Manager at Hovione in New Jersey described the US market as "fundamental for the company" and this investment as "a key step in our expansion strategy".
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance